NeuroSense Therapeutics (NASDAQ:NRSN) Cut to Hold at HC Wainwright

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports.

Several other brokerages have also issued reports on NRSN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Wednesday, October 28th. Roth Capital downgraded shares of NeuroSense Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $170.00.

NeuroSense Therapeutics Stock Down 28.1%

NeuroSense Therapeutics stock opened at $1.43 on Monday. The business’s 50-day simple moving average is $5.31 and its 200 day simple moving average is $12.80. The stock has a market cap of $2.71 million, a price-to-earnings ratio of -0.13 and a beta of 1.66. NeuroSense Therapeutics has a 12-month low of $1.10 and a 12-month high of $25.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned about 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is aimed at addressing multiple biological mechanisms associated with conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.

Its lead investigational product, PrimeC, is a proprietary oral combination formulation of ciprofloxacin and celecoxib designed to target pathways implicated in ALS, including neuroinflammation and RNA regulation.